HealthRX.com · Printable symptom log
Zepbound stop, hold or maintain plan with follow-up log
Write down why treatment is changing, what kind of change it is, the benefit you most want to keep and who owns follow-up, then log weight, waist, blood pressure, glucose and appetite after the last dose. It turns a generic taper question into a plan built around your own reason for stopping.
Where treatment stands today
Last injection date
Dose and strength at that injection
Device and doses leftdo not plan around leftover supply
What Zepbound is treatingweight management, sleep apnea, or both
Prescriber who owns this plan
Why treatment is changing
- Pregnancy, or planning a pregnancy
- Suspected pancreatitis, a serious allergic reaction or another urgent reaction
- Side effects that persist but are not an emergency
- Cost or loss of coverage
- Treatment goal reached
- A planned surgery or procedure
- Personal preference to stop
What kind of change this is
Tick one. A hold for a procedure is not the same decision as stopping for good.
- Permanent stop
- A hold, with a named person who decides the restart
- Continued treatment at a lower dose agreed with the prescriber
- Switch to another treatment
What needs protecting
The benefit that matters most to keep
Other weight, glucose, blood pressure or sleep treatments in use
The measurement or symptom that means call the care team
Who follows up, and when the first check-in is
Follow-up log after the change
Record the measures that matched the reason for treatment; there is no required testing calendar.
| Date | Weight | Waist (if measured) | Blood pressure | Glucose or HbA1c (if diabetic) | Appetite: less, same or more |
|---|---|---|---|---|---|
What the trials and the label found
- SURMOUNT-4: after a switch to placebo at week 36, mean weight rose 14.0% by week 88, while those who continued tirzepatide lost another 5.5%.[1]
- SURMOUNT-MAINTAIN: at week 112, mean change from the original baseline was -21.9% on the maximum tolerated dose, -16.6% on 5 mg and -9.9% on placebo.[2]
- In a SURMOUNT-4 post hoc analysis, larger regain after stopping went with larger increases in waist size and systolic blood pressure.[3]
- Tirzepatide's elimination half-life is about 5 to 6 days, so its effect fades gradually after the last dose rather than all at once.[4]
Stop Zepbound and get help or call your prescriber now
- Stomach pain that is severe or will not settle, sometimes spreading to the back: the label says to stop if pancreatitis is suspected.[4]
- Swelling of the face, lips, tongue or throat, or difficulty breathing or swallowing.[4]
- A positive pregnancy test: the label says to stop once pregnancy is recognized.[4]
Questions for the prescriber
- Is continued treatment at a lower dose an option instead of stopping?
- Which measurement or symptom should make me call, and how soon after the last dose should we check in?
- Do any of my other medicines need to change when Zepbound stops?
- If I want to restart later, who decides the dose, and what will you need to know?
- What will replace the benefit for my blood pressure, glucose or sleep apnea?
Sources for the facts on this sheet
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024. PMID 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/
- Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2026. PMID 42119587. https://pubmed.ncbi.nlm.nih.gov/42119587/
- Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med 2026. PMID 41284285. https://pubmed.ncbi.nlm.nih.gov/41284285/
- Eli Lilly and Company, via DailyMed. Zepbound (tirzepatide) injection, for subcutaneous use: prescribing information and Medication Guide. Effective 2026-08-28. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.